Hartmut J. Ehrlich

The COVID-19 Pandemic and Virtual Interviews in the 2020-2021 Resident Match

Hartmut J. Ehrlich, Adel Elkbuli, Mark George McKenney, Don K. Nakayama

The coronavirus-19 (COVID-19) pandemic imposed social distancing and limitations on travel that profoundly affected the resident selection processes of American general surgical postgraduate training programs. Traditionally candidates underwent in-person visits at training hospital sites, interviewed with attending staff and resident trainees and …

us (code pays fourni par la source)

S1095 Obefazimod in Patients With Moderate-to-Severe Ulcerative Colitis: Efficacy and Safety Analysis From the 96-Week Open-Label Maintenance Phase 2b Study

Severine A.R.A. Vermeire, Josianne Nitcheu, Paul Gineste, Sheldon Sloan et autres

Introduction: Obefazimod is an oral small molecule that modulates inflammation by upregulating a specific anti-inflammatory micro-RNA (miR-124). Obefazimod has demonstrated safety and efficacy in patients with moderate-to-severe ulcerative colitis (UC) in the randomized, placebo-controlled, phase 2b induction study (1). This analysis presents …

be, fr, us (code pays fourni par la source)

S1097 Correlation of miR-124 Upregulation and PK Parameters in Blood of Patients With Moderate-to-Severe Ulcerative Colitis Receiving Obefazimod for 16 Weeks

Julien Santo, Aurelien Flatres, Paul Gineste, Didier Scherrer et autres

Introduction: Obefazimod is an oral small molecule that has demonstrated short- and long-term efficacy and good safety profile in patients with moderate-to-severe ulcerative colitis (UC) (1,2). Obefazimod modulates inflammation by upregulating a specific anti-inflammatory micro-RNA (miR-124). In humans, obefazimod is metabolized via …

fr, us, be (code pays fourni par la source)

S1096 Long-Term Upregulation of miR-124 in Blood and Rectal Biopsies of Patients With Moderate-to-Severe Ulcerative Colitis Receiving Obefazimod 50mg Daily for 96 Weeks

Julien Santo, Aurelien Flatres, Paul Gineste, Didier Scherrer et autres

Introduction: Obefazimod is an oral small molecule that has demonstrated long-term efficacy and safety in patients with moderate-to-severe ulcerative colitis (UC) (1,2). Obefazimod is known to modulate inflammation by upregulating a specific anti-inflammatory micro-RNA (miR-124) (3). We examined the long-term effects of …

fr, us, be (code pays fourni par la source)

ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

Pedro Francisco Giavina-Bianchi Junior, Éric Cua, Karine Risso, V. Mondain et autres

Background ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. Objective We assessed the efficacy and safety of the standard of care (SoC) plus oral obefazimod …

br, fr (code pays fourni par la source)

Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis

Severine A.R.A. Vermeire, Virginia Solitano, Laurent Peyrin‐Biroulet, Herbert Tilg et autres

Biologic agents and oral small molecules are the mainstays of inflammatory bowel disease [IBD] management. However, an unmet clinical need remains for additional agents with novel mechanism of action which are effective, safe, and disease-modifying; this is due to the substantial proportion …

be, ca, it, fr, at, us (code pays fourni par la source)

EP148 OBEFAZIMOD UPREGULATES MIR-124 AND DOWNREGULATES THE EXPRESSION OF SOME CYTOKINES IN BLOOD AND RECTAL BIOPSIES OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS

Julien Santo, Paul Gineste, Didier Scherrer, Josianne Nitcheu et autres

Data from Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo

Filza Hussain, Michael Freissmuth, Dirk Völkel, Michael Thiele et autres

Abstract Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine, originally discovered for its eponymous effect and now known for pleiotropic biologic properties in immunology and oncology. Circulating MIF levels are elevated in several types of human cancer including prostate cancer. MIF …

Supplementary Figure from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models

Didier Scherrer, Noel Barrett, Luc Teyton, Tillman E. Pearce et autres

Supplementary Figure from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models

Supplementary Data from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models

Didier Scherrer, Noel Barrett, Luc Teyton, Tillman E. Pearce et autres

Supplementary Data from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models

Supplementary Figure from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models

Didier Scherrer, Noel Barrett, Luc Teyton, Tillman E. Pearce et autres

Supplementary Figure from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models

Supplementary Methods, Figures 1 - 3 from Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo

Filza Hussain, Michael Freissmuth, Dirk Völkel, Michael Thiele et autres

PDF file - 247K, Suppl. Fig. 1. Pharmacokinetics of BaxG03 after intravenous and intraperitoneal injection; Suppl. Fig. 2. Trough plasma concentrations of BaxG03 after 28 days of administration; Suppl. Fig. 3. Dose-dependent inhibition of xenograft outgrowth by BaxB01 and BaxM159.